1582776-38-2

Upstream product

• 1582776-36-0 5,8-diphenyl-2-naphthalenemethanol 
• 2459-25-8 methyl naphthalene-2-carboxylate 
• 99970-75-9 methyl 5,8-diiodo-2-naphthoate 
• 1582776-31-5 methyl 5,8-diphenyl-2-naphthoate 
• 298-12-4 Glyoxilic acid 
• 796-30-5 1,4-diphenylnaphthalene 

Downstream Products

• 1582776-65-5 (E)-4-[(5,8-(diphenyl)naphthalene-2-yl)ethenyl]benzoic acid 
• 1582776-67-7 (E)-3-fluoro-4-[(5,8-(diphenyl)naphthalene-2-yl)ethenyl]benzoic acid 
• 1582776-69-9 (E)-3-bromo-4-[(5,8-(diphenyl)naphthalene-2-yl)ethenyl]benzoic acid 
• 1582776-59-7 methyl ( E)-4-[2-(5,8-(diphenyl)naphthalen)-2-yl-ethenyl]benzoate 
• 1582776-61-1 methyl (E)-3-fluoro-4-[2-(5,8-(diphenyl)naphthalen-2-yl)ethenyl]benzoate 
• 1582776-63-3 methyl (E)-3-bromo-4-[2-(5,8-(diphenyl)naphthalen-2-yl)ethenyl]benzoate 

Relevant academic research and scientific papers

Singlet oxygen carrier for inhibiting beta-amyloid protein aggregation as well as preparation method and application thereof

The invention discloses a singlet oxygen carrier for inhibiting beta-amyloid protein aggregation as well as a preparation method and application thereof, which belongs to the technical field of biological medicines. The singlet oxygen carrier for inhibiting beta-amyloid protein aggregation contains two functional groups, namely a benzothiazole group and a singlet oxygen carrier. The benzothiazole group can be selectively combined with the beta-amyloid protein, so that the targeting property of the system is improved, the aggregation of the beta-amyloid protein is inhibited, and the neurotoxicity caused by the beta-amyloid protein is reduced. The endoperoxide in the system can release singlet oxygen under a certain condition, and the singlet oxygen can oxidize the beta-amyloid protein, so that the aggregation of the beta-amyloid protein is further limited, and the toxicity is reduced. The carrier has dual inhibition effects on beta-amyloid protein, and has application potentials of treating related diseases caused by beta-amyloid protein aggregation and relieving Alzheimer's disease and other diseases.

Dual RXR agonists and RAR antagonists based on the stilbene retinoid scaffold

Arotinoids containing a C5,C8-diphenylnaphthalene-2-yl ring linked to a (C3-halogenated) benzoic acid via an ethenyl connector (but not the corresponding naphthamides), which are prepared by Horner-Wadsworth-Emmons reaction of naphthaldehydes and benzylphosphonates, display the rather unusual property of being RXR agonists (15-fold induction of the RXR reporter cell line was achieved at 3- to 10-fold lower concentration than 9-cis-retinoic acid) and RAR antagonists as shown by transient transactivation studies. The binding of such bulky ligands suggests that the RXR ligand-binding domain is endowed with some degree of structural elasticity.